Last reviewed · How we verify
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 is a HIV-1 vaccine Biologic drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently in Phase 3 development for HIV-1 prevention in at-risk populations.
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 are recombinant gp120 envelope protein vaccines designed to elicit immune responses against HIV-1 by presenting the viral surface antigen.
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 are recombinant gp120 envelope protein vaccines designed to elicit immune responses against HIV-1 by presenting the viral surface antigen. Used for HIV-1 prevention in at-risk populations.
At a glance
| Generic name | MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | HIV-1 vaccine |
| Target | gp120 (HIV-1 envelope glycoprotein) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
These vaccines contain recombinant gp120 proteins from different HIV-1 strains (MN and GNE8) that serve as immunogens to stimulate both humoral and cellular immune responses against the HIV-1 envelope. By exposing the immune system to these viral surface proteins, the vaccines aim to generate neutralizing antibodies and T-cell responses that can recognize and eliminate HIV-1-infected cells or prevent infection.
Approved indications
- HIV-1 prevention in at-risk populations
Common side effects
- Injection site reactions (pain, erythema, induration)
- Fever
- Fatigue
- Myalgia
Key clinical trials
- A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers (PHASE2)
- A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers (PHASE1)
- A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers (PHASE1)
- Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B (PHASE2)
- A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines (PHASE1)
- Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 CI brief — competitive landscape report
- MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI
Frequently asked questions about MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
What is MN rgp120/HIV-1 and GNE8 rgp120/HIV-1?
How does MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 work?
What is MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 used for?
Who makes MN rgp120/HIV-1 and GNE8 rgp120/HIV-1?
What drug class is MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 in?
What development phase is MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 in?
What are the side effects of MN rgp120/HIV-1 and GNE8 rgp120/HIV-1?
What does MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 target?
Related
- Drug class: All HIV-1 vaccine drugs
- Target: All drugs targeting gp120 (HIV-1 envelope glycoprotein)
- Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for HIV-1 prevention in at-risk populations